Nektar Therapeutics (NASDAQ: NKTR) kicked off on Monday, down -7.17% from the previous trading day, before settling in for the closing price of $46.84. Over the past 52 weeks, NKTR has traded in a range of $0.43-$66.92.
Annual sales at Healthcare sector company grew by 25.49% over the past five years. While this was happening, its average annual earnings per share was recorded -14.85%. With a float of $20.07 million, this company’s outstanding shares have now reached $20.34 million.
Nektar Therapeutics (NKTR) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Nektar Therapeutics is 1.35%, while institutional ownership is 70.48%. The most recent insider transaction that took place on Nov 25 ’25, was worth 62,802. In this transaction Chief R&D Officer of this company sold 1,157 shares at a rate of $54.28, taking the stock ownership to the 18,971 shares. Before that another transaction happened on Nov 25 ’25, when Company’s Chief Legal Officer sold 630 for $54.28, making the entire transaction worth $34,196. This insider now owns 21,585 shares in total.
Nektar Therapeutics (NKTR) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -2.25 earnings per share (EPS), higher than consensus estimate (set at -2.92) by 0.67. Wall Street market experts anticipate that the next fiscal year will bring earnings of -2.59 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -14.85% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -8.99% during the next five years compared to 25.49% growth over the previous five years of trading.
Nektar Therapeutics (NASDAQ: NKTR) Trading Performance Indicators
Take a look at Nektar Therapeutics’s (NKTR) current performance indicators. Last quarter, stock had a quick ratio of 4.24. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 14.13.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -7.94, a number that is poised to hit -2.41 in the next quarter and is forecasted to reach -9.79 in one year’s time.
Technical Analysis of Nektar Therapeutics (NKTR)
Nektar Therapeutics (NASDAQ: NKTR) saw its 5-day average volume 2.11 million, a positive change from its year-to-date volume of 0.9 million. As of the previous 9 days, the stock’s Stochastic %D was 12.99%.
During the past 100 days, Nektar Therapeutics’s (NKTR) raw stochastic average was set at 48.93%, which indicates a significant increase from 5.18% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 4.15 in the past 14 days, which was higher than the 3.53 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $57.15, while its 200-day Moving Average is $31.68. Nevertheless, the first resistance level for the watch stands at $45.91 in the near term. At $48.35, the stock is likely to face the second major resistance level. The third major resistance level sits at $49.79. If the price goes on to break the first support level at $42.03, it is likely to go to the next support level at $40.59. Assuming the price breaks the second support level, the third support level stands at $38.15.
Nektar Therapeutics (NASDAQ: NKTR) Key Stats
The company with the Market Capitalisation of 884.45 million has total of 20,342K Shares Outstanding. Its annual sales at the moment are 98,430 K in contrast with the sum of -118,960 K annual income. Company’s last quarter sales were recorded 11,790 K and last quarter income was -35,520 K.
